Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia.
Tongting JiYang YangJuanjuan YuHongli YinXinran ChuPengju YangLing XuXiaodong WangShaoyan HuYizhen LiXiaochen WuWengyuan LiuBi ZhouWenjuan WangShuqi ZhangWei ChengYanling ChenLei ShiZhiheng LiRan ZhuoYongping ZhangYanfang TaoDi WuXiaolu LiZimu ZhangJun-Jie FanJian PanJun LuPublished in: Journal of experimental & clinical cancer research : CR (2024)
Our study revealed that indisulam, which targets RBM39 to induce tumor cell apoptosis, is an effective drug for treating T-ALL. Targeting RBM39 through indisulam leads to mis-splicing of pre-mRNAs, resulting in the loss of key effectors such as THOC1.